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We  examined  the  pathogenesis  of glomerular  damage  in Th2  type-dependent  GATA-3  transgenic  (GATA-
3  Tg)  mice  with  IgA  nephropathy  (IgAN).  GATA-3  Tg  mice  were  immunized  orally  using  OVA  plus  cholera
toxin  B (CTB),  and  measurement  of  the  serum  IgA  antibody  level  and  histopathological  examination
were  performed.  Marked  increases  in  the  serum  levels  of  OVA-speciﬁc  IgA  antibody,  IgA  and  IgG, C3
deposits  analogous  to those  seen  in  IgAN,  and  expansion  of  the  matrix  in association  with  mesangial
cell  proliferation  were  observed.  Furthermore,  glomerular  IgA  deposits  were  co-localized  with mannan-
binding  lectin  (MBL)  deposits,  which  might  actually  have  been  abnormal  IgA  deposits.  In  GATA-3/TCR-Tg
mice  that had  been  orally  sensitized  with  CTB  plus  OVA  and  were  re-stimulated  with  OVA in  vitro,
cultured  Peyer’s  patch  cells  showed  the  enhanced  production  of IL-5  and  supernatants  from  cultures  of
spleen  cells  showed  a  reduction  of  TGF-  production  with  a simultaneous  increase  in  IL-2 production
and  the  recovery  of  IFN-  formation.  The  amount  of TGF-  produced  by the  spleen  cells  was  found  to be
correlated  with  the  amount  of  IFN-  and  IL-IL-2  produced  by  the  cells.  Also,  the  percentage  of  regulatory
T  cells  (Treg)  in the  spleens  of  mice  sensitized  with  OVA  plus  CTB  was  lower  than  that  in  mice  orally
sensitized  with  OVA  alone.  These  results  suggest  that  the  increased  production  of  IL-5  from  Peyer’s  patch
cells  (PPc)  and  the  restored  Th1-type  immune  response  might  cause  the production  of abnormal  IgA  and
might induce  the  deposition  of  IgA  in  glomeruli.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC. Introduction
Immunoglobulin A (IgA) nephropathy was ﬁrst described in
968 (Berger and Hinglais, 1968) and is now generally regarded
orldwide as the most common form of primary glomerulonephri-is. IgA nephropathy (IgAN) accounts for approximately half of the
ases of primary glomerulonephritis in Japan, with the disease pro-
∗ Corresponding author.
E-mail address: hidetama@epu.ac.jp (H. Tamauchi).
ttp://dx.doi.org/10.1016/j.imbio.2015.12.001
171-2985/© 2015 The Authors. Published by Elsevier GmbH. This is an open access artic
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
gressing to end-stage renal failure in about 30–40% of all cases
(Wakai et al., 1999).
The cause of primary IgAN is unknown. No consistent infec-
tious or environmental agents have been identiﬁed that can be
considered as being deﬁnitively responsible for the IgA-antibody
response. IgAN occurs sporadically, and there is no evidence
to suggest any familial pattern of inheritance of this condition.
Nevertheless, immunogenetic factors may  predispose some indi-
viduals to IgA nephropathy, as familial clustering has been reported
(Scolari, 1999; Scolari et al., 1999; Song and Wei, 2003; Shin and
Lee, 2008). Primary IgAN is a form of immune-complex-mediated
glomerulonephritis and is characterized immunohistologically by
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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he presence of IgA deposits in the glomeruli, accompanied by
 variety of histological lesions. The identiﬁcation of the mecha-
isms responsible for the development and progression of IgAN is
rgently needed, as the disease often progresses to end-stage renal
isease. IgAN that is characterized by the deposition of IgA and
omplement C3 in the glomerular mesangial region is generally
hought to be an inﬂammatory-immune disease associated with
gA or IgA immune complex deposits and complement activation,
nd its pathogenesis has been investigated from both the aspects of
umoral immunity and cell-mediated immunity (Holdsworth et al.,
999; Kitching et al., 2003).
Clinical and histopathologic observations suggest that the
ucosal immune system plays an important role in the patho-
enesis of some forms of human immune complex-associated
lomerulonephritis. For example, many studies of idiopathic
ecurrent hematuria and glomerulonephritis associated with ana-
hylactoid purpura, in which IgA is the predominant or only
mmunoglobulin deposited in the glomeruli, have reported a clin-
cal association between kidney damage and viral-like respiratory
nd gastrointestinal syndromes (Roy et al., 1973; Katz et al., 1976;
ernandez et al., 1997). Furthermore, much of the IgA in the body
s derived from the gut and respiratory-associated lymphoid tissue,
nd an expansion of speciﬁc IgA-synthesizing cells to the mesen-
eric lymph nodes, spleen, and secretory mucosa, together with a
igniﬁcant elevation in the levels of IgA in the serum and exocrine
uids, can occur in response to oral immunization (Ruedl et al.,
996). Thus, the onset of IgAN may  be associated with infections
f the upper respiratory tract. Accordingly, IgAN may  result from
yperreactivity of the mucosal immune system.
In recent years, abnormal IgA glycosylation has been discussed
n relation to the pathogenesis of IgAN. The induction of abnormal
gA glycosylation by Th2 cytokines and the involvement of these
ytokines in Th2-dependent modiﬁcations of the sugar chain in
he tonsillar and gastrointestinal mucosa have also been demon-
trated (Chintalacharuvu and Emancipator, 1997; Chintalacharuvu
t al., 2001, 2008; Kobayashi et al., 2002; Yamada et al., 2010). We
xamined the pathogenesis of glomerular IgA deposition using a
ouble-transgenic mouse model, in which GATA-3 transgenic mice
ere crossed with OVA-recognition T cell receptor transgenic mice,
o determine the contribution of mucosal immunity to the patho-
enesis of IgAN. Furthermore, the relation to systemic immunity
as also examined.
. Materials and methods
.1. Mice
GATA-3 gene-introduced transgenic (GATA-3-Tg) mice were
repared by introducing a 7.2-kb-Not I linearized fragment with
 lck distal promoter into an uncleaved fertilized ovum from
 C57BL/6 mouse. The hemizygous GATA-3-Tg mice were then
rossed with homozygous OVA323–339 peptide-speciﬁc T cell recep-
or gene-introduced transgenic (TCR-Tg) mice in the context of I-Ad
estriction. These double-transgenic and non-GATA-3/TCR trans-
enic mice were designated as GATA-3/TCR-Tg and WT/TCR-Tg
ice, respectively (Tamauchi et al., 2005). The mice were used in
he experiments at about 10 weeks of age. Each experimental group
onsisted of at least 5 mice. All the experiments were conducted in
ccordance with the Guidelines for Animal Experimentation pub-
ished by the Japanese Association for Laboratory Animal Science
1987). The protocol of this study was approved by the Animal Care
nd Use Committee for Experimental Animals of Kitasato Univer-
ity. Mice were maintained under speciﬁc pathogen-free conditions
n our animal facilities.logy 221 (2016) 577–585
2.2. Immunization and challenge protocol
GATA-3/TCR-Tg and WT/TCR-Tg mice were immunized orally
with cholera toxin B (CTB; 10 g; Calbiochem, Germany) alone
(protocol b) or with OVA (OVA grade V; 5 mg;  Sigma–Aldrich, St.
Louis, USA) alone (protocol c) or with CTB plus OVA (5 mg;  protocol
a) three times at one-week intervals. The animals were then given
an additional oral dose of OVA (50 mg)  seven days after the last
OVA-plus-CTB administration, followed by the collection of sam-
ples 4 days after the last OVA administration. As a control group,
we administered 0.2 mL  of phosphate-buffered saline (PBS) instead
of the OVA challenge.
2.3. Histopathological assessment of renal tissues
Kidney tissue specimens were quickly frozen in liquid nitrogen
and ﬁxed in 10% buffered formalin. The formalin sections were
stained with hematoxylin and eosin or periodic acid Schiff. Thin
sections of the frozen tissues (about 3 m thick) were cut using a
cryostat, and ﬂuorescent staining was  performed at room tempera-
ture. For direct immunoﬂuorescence, FITC-labeled goat anti-mouse
IgG and C3 antibodies (Capel, Aurora, Ohio), FITC-labeled goat anti-
mouse IgA antibody (Santa Cruz Biotechnology, Santa Cruz, CA),
and FITC-labeled rat anti-mouse IgG1 and IgG2a antibodies (BD
Pharmingen, San Diego, CA)  were used. Biotin-labeled mannan-
binding lectin (MBL) antibody was provided by Dr. M.  Matsushita
(Tokai University School of Engineering, Hiratsuka Kanagawa). The
stained preparations were examined using a Zeiss dark-ﬁeld ﬂuo-
rescence microscope. Staining for MBL  was  also performed using
the enzyme-labeled antibody method and the avidin-biotinylated
peroxidase complex technique. The sections were pretreated using
the Avidin/Biotin Blocking Kit (Vector, UK) before staining. The lev-
els of renal damage were then assessed using PAS-stained sections.
2.4. Measurement of OVA-speciﬁc IgA antibody in sera
OVA-speciﬁc IgA antibodies in the sera of immunized mice were
measured using a sandwich enzyme-linked immunosorbent assay
(ELISA), as described previously (Tamauchi et al., 2005). Each serum
sample, as well as serial dilutions of the control sample, was incu-
bated in a 96-well microtiter plate coated with OVA (100 g/mL;
Sigma). After incubation, biotin-labeled rat monoclonal antibodies
(mAb) against mouse IgA (Zymed Laboratories, South San Francisco,
CA) were incubated with streptavidin-horseradish peroxidase (BD
Pharmingen, San Diego, CA). Finally, the plates were subjected to
a peroxidase reaction in a tetramethylbenzidine (TMB) substrate
solution for color development and analyzed at 450 nm using an
ELISA plate reader.
2.5. Cytokines production assay of culture supernatants
GATA-3/TCR-Tg mice and WT/TCR-Tg mice were orally immu-
nized with OVA or OVA plus CTB three times at one-week intervals.
Four days after the last immunization, the animals were sacriﬁced
and the Peyer’s patch and spleen were removed and used to make
cell suspensions. The Peyer’s patch and spleen cells (5 × 105/well)
were then cultured for 48 h at 37 ◦C under 5% CO2 in 96-well
ﬂat-bottomed plates containing the indicated concentrations of
puriﬁed OVA grade V (Sigma Chemical Co., St. Louise, MO). The lev-
els of IFN-, IL-2, IL-4, and IL-5 in the supernatants obtained from
the cultured cells were determined using ELISA assay kits (Endogen,
Cambridge, MA)  as well as TGF- (R&D Systems, UK). Cells with a
survival rate of 95% or more were used.
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Table  1
Immunostaining of IgA, IgG1, IgG2a and C3 in Kidney of the OVA-plus-CTB immunized GATA-3/TCR Tg mice.
No. of positive mice/No. of total mice (%)
Strain Immunization Challenge IgA C3 IgG1 IgG2a
WT/TCR CTB OVA 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
WT/TCR OVA OVA 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
WT/TCR OVA + CTB OVA 2/10 (20) 2/10 (20) 10/10 (100) 0/10 (0)
GATA-3/TCR CTB OVA 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
GATA-3/TCR OVA OVA 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
GATA-3/TCR OVA + CTB OVA 9/10 (90) 9/10 (90) 10/10 (100) 9/10 (90)
Note: GATA-3/TCR-Tg mice and WT/TCR-Tg mice were treated with OVA, CTB alone orally or OVA plus CTB orally. OVA and the adjuvant were administered three times at
one-week intervals, followed by the oral administration of OVA seven days after the last immunization. Four days after the OVA challenge, the renal tissues were frozen in
liquid  nitrogen. Sections were then stained with immunoﬂuorescent antibodies for IgA, IgG1, IgG2a or C3. The sections were observed at a magniﬁcation of ×200.
Fig. 1. Experimental protocols.
Protocol a: OVA (5 mg)  and CTB (10 g) were administered orally to GATA-3/TCR-Tg
and WT/TCR-Tg mice on days 0, 7, and 14. Protocol b: GATA-3/TCR-Tg and WT/TCR-
Tg  mice were immunized with CTB (10 g) alone on days 0, 7, and 14. Protocol c:
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Fig. 2. Changes in renal tissues according to OVA and adjuvant administration.
Sections were stained with immunoﬂuorescent antibodies for FITC-labeled anti-
mouse IgA or C3 (Santa Cruz) and were stained with PAS. Sections were then stained
with immunoﬂuorescent antibodies for FITC-labeled rat anti-mouse IgG1 and IgG2ATA-3/TCR-Tg and WT/TCR mice were inoculated with OVA (5 mg)  alone on days 0,
,  and 14. In each of the protocols, OVA (50 mg)  was  administered orally 7 days after
he  last immunization. Samples were obtained four days after the OVA challenge.
.6. Flow-cytometric analysis
Three days after the oral OVA challenge of GATA-3/TCR-Tg mice
ensitized with OVA plus CTB, the spleen and Peyer’s patches of
he mice were removed and cell suspensions were prepared. The
reg cells were stained with the Mouse Regulatory T cell Staining
it (eBioscience, San Diego CA), washed with Foxp3 staining buffer,
nd analyzed using FACScan.
.7. Statistical analysis
Statistical signiﬁcance was determined using an unpaired t-test
comparison of two groups) or a one-way ANOVA (comparison of
hree or more groups). The results are expressed as the mean ± S.D.
ifferences of P < 0.05 were considered to indicate statistical signif-
cance.
. Results
.1. Immunopathological ﬁndings in the kidney and their
orrelations with serum OVA-speciﬁc IgA antibody titers
At ﬁrst, we examined GATA-3 Tg mice using the immunological
ethod shown in Fig. 1 to determine the immunological mech-
nism underlying the deposition of IgA in the glomeruli in IgA
ephropathy.
The renal tissues of the GATA-3/TCR-Tg mice orally immunized
ith OVA-plus-CTB showed marked deposition of IgA, IgG2a, andantibodies (Santa Cruz). The sections were observed at a magniﬁcation of ×200.
C3 and the expansion of the matrix associated with mesangial cell
proliferation in the kidney; these observations were analogous to
those seen in clinical cases of IgAN in humans. The deposition
of IgA, C3, and IgG2a was observed in 90% of the OVA-plus-
CTB-immunized GATA-3/TCR-Tg mice. In the WT/TCR-Tg mice,
however, the deposition of IgA, C3, and IgG2a was observed in less
than 20% of the OVA-plus-CTB-immunized mice (Table 1).
Regarding IgA deposition, the OVA-plus-CTB-immunized/OVA-
challenged WT/TCR-Tg mice exhibited a much weaker deposition
than the OVA-plus-CTB-immunized/OVA-challenged GATA-3/TCR-
Tg mice (Fig. 2). The deposition of Th1-dependent IgG2a was not
observed in the glomeruli of the IgA deposition-negative OVA-
plus-CTB-immunized/OVA-challenged WT/TCR-Tg mice. However,
the marked deposition of Th2-dependent IgG1 was found in the
glomeruli of both the OVA-plus-CTB-immunized/OVA-challenged
GATA-3/TCR-Tg and WT/TCR-Tg mice (Fig. 2 and Table 1). No his-
tological changes were found in the glomeruli of mice immunized
with CTB or OVA alone (Table 1).
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Fig. 3. Production of OVA-speciﬁc IgA antibody in serum through the oral adminis-
tration of OVA plus CTB.
Serum OVA-speciﬁc IgA levels in CTB-immunized or OVA-plus-CTB-immunized
GATA-3/TCR-Tg and WT/TCR-Tg mice that received a subsequent OVA challenge.
Data are the mean ± SD for a group of ﬁve mice and are representative of three
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iependent experiments. P < 0.05 vs. OVA-plus-adjuvant (CTB)-immunized/OVA-
lus-CTB-challenged WT/TCR-Tg mice. GATA-3/TCR-Tg: closed, WT/TCR-Tg:
lashed.
We  measured the OVA-speciﬁc IgA antibody titers in
erum samples obtained from OVA-plus-CTB-immunized/OVA-
hallenged mice and found that the OVA-speciﬁc IgA antibody
iter was approximately ﬁve times higher in the GATA-3/TCR-Tg
ice than in the WT/TCR-Tg mice (Fig. 3). Although the data are
ot shown, we did not ﬁnd any differences in the changes in the
evel of OVA-speciﬁc IgA antibody in the serum following the
dministration of OVA alone. We  were also unable to recognize
ny differences in the antibody levels between the GATA-3/TCR-Tg
nd WT/TCR-Tg mice following the administration of only CTB
hree times. Furthermore, the antibody titers were similar in the
on-immunized GATA-3/TCR-Tg and WT/TCR-Tg mice (OD450
.9 ∼ 1.0). In addition, no signiﬁcant difference in the production
f IgA was observed between the non-immunized GATA-3/TCR-Tg
ice and the WT/TCR-Tg mice.
We  examined the deposition of IgA and MBL  because the depo-
ition of MBL, which consists of molecules participating in the
ectin pathway, has been reported in IgAN. We  found that IgA
nd MBL  deposits were colocalized in the mesangial region in the
VA-plus-CTB-immunized/OVA-challenged GATA-3/TCR-Tg mice.
owever, in the OVA-plus-CTB-immunized/OVA-challenged WT-
CR-Tg mice, no deposits of either IgA or MBL  were found (Fig. 4).
Oral antigen sensitization using CTB may  have resulted in a
arbohydrate chain abnormality in the IgA produced in GATA-
/TCR-Tg mice, in which the Th1/Th2 balance of the immune system
as strongly tilted towards Th2-type immunity.
.2. Production of Th1 and Th2 cytokines from the spleen cells
nd Peyer’s patch cells following oral immunization
We  obtained spleen cells from GATA-3/TCR-Tg mice sensitized
rally with OVA alone or OVA plus CTB and re-stimulated the
ells with OVA antigen in vitro to further examine the cytokine
roduction. The production of IFN- and IL-2, which are Th1-
ype cytokines, was inhibited (Fig. 5a) in the GATA-3/TCR-Tg
ice immunized with OVA alone, compared with that in non-
mmunized GATA-3/TCR-Tg mice. For IFN- production, a notablylogy 221 (2016) 577–585
signiﬁcant difference was recognized. On the other hand, no
changes in the production of IL-5, which is a Th2-type cytokine, or
TGF- were observed (Fig. 5b and c). However, the production of
IL-4 was  about 1.5–2 times higher in the immunized GATA-3/TCR-
Tg mice than in similarly immunized WT/TCR-Tg mice. When
stimulated with OVA concentrations from 500 to 1000 g/mL, a sig-
niﬁcant difference was  found in the level of IL-4 production from
the spleen cells of GATA-3/TCR-Tg and WT/TCR-Tg mice. In the mice
treated with OVA plus CTB, IL-2 and IFN- production was restored,
compared with that observed in the mice treated with OVA alone,
and the production levels of these cytokines were similar to those
seen during a normal murine response. A more moderate suppres-
sion of the production of IL-4 and TGF- was observed, compared
with that in the untreated mice. IL-4 production was inhibited to
the same extent as that in the untreated mice, whereas the IL-2 and
IFN- production levels were restored to the same extent as that in
the untreated mice (Fig. 5b and c).
In the PPc obtained from the GATA-3/TCR-Tg mice, a three-fold
to four-fold increase in the production of IL-5 and an approximately
1.5-fold increase in the production of IL-4 were observed in ani-
mals treated orally with CTB plus OVA, compared with that in PPc
from OVA-plus-CTB-immunized WT/TCR-Tg mice. In PPc obtained
from OVA-plus-CTB-immunized or OVA-alone-immunized GATA-
3/TCR-Tg mice, the degree of IL-2 and IFN- production was the
same as that in PPc from WT/TCR-Tg mice. As for the quantity of
TGF- produced by the PPc, no differences were observed between
the groups. TGF- was produced regardless of the presence or
absence of antigen sensitization. However, when combined with
CTB, the quantity of TGF- production increased, but this response
was not speciﬁc to GATA-3/TCR-Tg mice. In mice sensitized with
OVA alone, the proﬁle of TGF- produced from the spleen was
similar to that for PPc from GATA-3/TCR-Tg and WT/TCR-Tg mice.
However, the amount of TGF- produced by the spleen cells from
the CTB-plus-OVA-immunized GATA-3/TCR-Tg mice was antigen-
dependent, except in the group treated orally with OVA (Fig. 5c).
3.3. Analysis of Treg populations in the spleen and Peyer’s patches
from GATA-3/TCR-Tg mice sensitized with OVA plus CTB
We  measured the numbers of CD4+Foxp3+ cells in the spleen and
Peyer’s patches of GATA-3/TCR-Tg mice sensitized with OVA  plus
CTB using a FACScan. The results revealed that after the adminis-
tration of OVA, both the GATA-3/TCR-Tg mice and the WT/TCR-Tg
mice showed an approximately 1.5-fold increase in the number of
CD4+Foxp3+ cells in the spleen, compared with the levels in respec-
tive non-treated Tg mice. In the Peyer’s patches, on the other hand,
the percentage of CD4+Foxp3+ cells decreased in both the GATA-
3/TCR-Tg and WT/TCR-Tg mice following the oral administration
of OVA. These changes in the numbers of CD4+Foxp3+ cells (Fig. 6)
were similar to those observed for TGF- production, as shown in
Fig. 5.
The addition of CTB was  suggested to control the Treg cells.
Also, both the spleen and Peyer’s patches of the OVA-plus-CTB-
immunized mice showed equivalent percentages of Treg cells,
compared with the percentages for the spleen and Peyer’s patches
of untreated GATA-3/TCR and WT/TCR mice. The percentages of
Treg cells were also similar in untreated and OVA-alone-treated
mice of both genotypes. From these results, the cytokine produc-
tion and proportion of Treg cells appeared to show contradictory
responses in the spleen and Peyer’s patches, and CTB could be
responsible for regulating the immune response.4. Discussion
Recently, tonsillectomy plus steroid pulse therapy for the
treatment of IgAN has received considerable attention, with the
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Fig. 4. Correlation between MBL-positive cells and IgA-positive cells in OVA-plus-CTB-immunized GATA-3/TCR-Tg mice.
GATA-3/TCR-Tg and WT/TCR-Tg mice were treated with CTB plus OVA orally three times at one-week intervals, followed by the oral administration of OVA seven days after
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Ohe  last immunization. At four days after the OVA challenge, the renal tissues were ﬁ
inding lectin (MBL) antibody, followed by reaction with avidin-labeled Texas Red u
nti-mouse IgA antibodies (Santa Cruz). The stained preparations were examined u
herapeutic response reportedly varying with the interval from
he onset of the abnormal urinalysis ﬁndings until the initiation
f treatment (Ieiri et al., 2007). The remission rate is high in
atients with early treatment and declines with an increasing inter-
al between disease onset and treatment initiation. Based on these
bservations, we suggested that the cells responsible for the devel-
pment of IgAN may  be present in the mucosa, including the tonsils,
uring the early phase of the disorder and may  migrate from the
ucosa to the secondary lymph nodes as well as the bone mar-
ow and spleen in the later phases. Thus, immune responses in the
ucosa are likely to be vital in the development of IgAN.
The present study was conducted using GATA-3-Tg mice that
onstantly express the GATA-3 gene, tilting the Th1/Th2 balance
owards Th2 dominance, with the aim of examining the pathogen-
sis of IgAN by clarifying the mechanism of the production and
eposition of IgA in these animal models (Tamauchi et al., 2004).
In mice orally immunized with OVA plus CTB, IgA deposits were
vident in the kidney, and these IgA deposits were colocalized
ith MBL  deposits (Fig. 4). OVA-speciﬁc IgA has been suggested
o consist of abnormally glycosylated IgA (Oortwijn et al., 2006;
ashimoto et al., 2012).
The Th2-type cytokines IL-4 and IL-5 have been reported to
e involved in the glycosylation of IgA. As a cause of the depo-
ition of IgA in the kidney, the abnormal glycosylation of IgA
as been suggested, and the Th2-type cytokine IL-4 is report-
dly important for such abnormal glycosylation (Chintalacharuvu
t al., 2001; Yamada et al., 2010). At the time, however, an asso-
iation between the Th2-type cytokine IL-5 produced by PPc and
he deposition of IgA had been suggested. Regarding the produc-
ion of IL-4, we recognized a statistically signiﬁcant difference in
he level of IL-4 produced by PPc from WT/TCR-Tg, compared with
hat produced by PPc from GATA-3/TCR-Tg mice. However, the
roduction of IL-5 was thought to play an important role in IgA
eposition in the glomerulus because the production of IL-5 was
uch higher than that of IL-4 in PPc. Recently, glycosyltransferase
f -N-acetylgalactosaminide -2,6-sialyltransferase 2 and -1,3-
alactosyltransferase were reported to induce the deposition of IgA
n the glomerulus in response to IL-6 (Suzuki et al., 2014).
In addition, IFN-, a Th1-type cytokine, has also been reported
o be involved in glycosylation (Chintalacharuvu et al., 2001).
ral immunization with either OVA or CTB alone did not evoken liquid nitrogen. The renal tissues were then reacted with biotin-labeled mannan-
n indirect immunoﬂuorescence method for double-staining with FITC-labeled goat
 Zeiss dark-ﬁeld ﬂuorescence microscope (×200).
any signiﬁcant changes in the serum IgA antibody titers or the
degrees of IgA deposition in the kidney, indicating that the oral
co-administration of CTB as a mucosal adjuvant together with the
antigen (OVA) was  important for inducing IgA deposition in the
kidney. With a view to further clarifying the mechanism of produc-
tion of the deposited IgA, PPc and spleen cells obtained from mice
that had been orally immunized with OVA alone or with OVA plus
CTB three times at one-week intervals were re-exposed to the anti-
gen (OVA) in vitro, followed by assays of the culture supernatants
collected after 48 h of incubation and analyzed using ELISA for Th1
and Th2 cytokines (IFN-, IL-2, IL-4, IL-5, and TGF-) to assess the
Th1/Th2 balance. A marked enhancement of IL-5 production was
noted in the 48-h cultures of PPc obtained from GATA-3/TCR-Tg
mice immunized with OVA plus CTB. Oral sensitization with OVA
inhibited the production of IL-2 and IFN- from the spleen cells.
However, in the cultures of spleen cells obtained from GATA-3/TCR-
Tg and WT/TCR-Tg mice orally immunized with OVA plus CTB,
TGF- production was  suppressed, while IL-2 production remained
stable and IFN- production tended to be restored. A previously
published report described the role of the immune response to CTB
(Elson and Ealding, 1984; Iijima et al., 1998; Marinaro et al., 1995).
We have also reported that IL-2-dependent anergy was induced by
the oral administration of OVA (Tamauchi et al., 2005). In vitro,
the production of IFN- and IL-2 from the spleen cells of OVA-
inoculated mice was remarkably inhibited, compared with that
of untreated mice, when the murine spleen cells were stimulated
with OVA. However, we clariﬁed that the production of IFN- was
restored by the addition of IL-2 during OVA stimulation (Tamauchi
et al., 2005).
We were able to show that the IgA antibody responses in
mucosal lymphoid tissues, such as Peyer’s patches, generally
involve a predominance of IgA production (data not shown). An
increase in IgA production was  observed in the spleen of the GATA-
3/TCR-Tg mice after the oral administration of OVA plus CTB in this
experimental system (Fig. 3). A proliferation of TGF--positive cells
was also observed in this model (data not shown). TGF- is an
inhibitory cytokine secreted by regulatory T cells, which include
+ +CD4 Foxp3 -regulating T cells as endogenous constitutive regu-
latory T cells, and Th3 and Tr1 cells as inductive regulatory T
cells. Immune tolerance arising from IL-2-dependent energy was
induced in the spleen of the GATA-3/TCR Tg mice by oral sensitiza-
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Fig. 5. Production of cytokines in spleen and Payer’s patch cells from OVA-plus-CTB-immunized/OVA-challenged GATA-3/TCR-Tg mice.
Spleen and Payer’s patch cells were obtained from GATA-3/TCR-Tg and WT/TCR-Tg mice that had been orally immunized with OVA plus CTB three times at one-week
intervals; the cells were re-stimulated with OVA in vitro for 48 h, and the supernatants were recovered and assayed using ELISA kits for (a) IFN- and IL-2, (b) IL-4 and IL-5,
and  (c) TGF-. Data are the mean ± S.D. of three independent experiments. Signiﬁcant differences in the cytokine levels produced by the spleen and Peyer’s patch cells of
GATA-3/TCR-Tg and WT/TCR-Tg mice sensitized with OVA plus CTB were observed. #P < 0.05 and *P < 0.01.
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Fig. 6. Manifestation of CD4+ Foxp-3+ cells in spleen and Peyer’s patch cells from OVA-plus-CTB-immunized and OVA-challenged GATA-3/TCR-Tg mice.
GATA-3/TCR Tg mice were treated with CTB plus OVA orally three times at one-week intervals, followed by the administration of OVA orally at seven days after the last
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ntibody. The cells were stained using a Foxp3 staining kit with PE-labeled anti-CD
re  representative of three independent experiments with similar results (error bar
ion with OVA, indicating that the TGF--positive cells were highly
ikely to be CD4+Foxp3+-regulating T cells. When the lymphocytes
f the Peyer’s patches of the GATA-3/TCR-Tg mice sensitized with
VA plus CTB were challenged with OVA, the amount of TGF- pro-
uced by the cells was the same as that produced by Peyer’s patch
ymphocytes from WT/TCR-Tg mice sensitized with OVA plus CTB
nd then challenged with OVA.
TGF- is reportedly produced by Treg (CD4+Foxp3+) (Smaldini
t al., 2015). Also, we conﬁrmed that CD4+CD25+Foxp3+ cells and
GF-+cells were equivalent in this study using immunohistologi-
al studies (data not shown). The results of this study clearly show
hat TGF- in the periphery controls IFN- production. Moderate
GF- production was observed in PPc from OVA-alone-inoculated
ice, compared with untreated mice, but the difference was  not
tatistically signiﬁcant. In in vitro studies, the production of TGF-
ncreased according to the antigen quantity, similar to the produc-
ion of TGF- in the spleen in mice not treated with OVA. However,
n the OVA-treated group, the production of a ﬁxed level of TGF-
as always observed regardless of the quantity of antigen used for
timulation. As for the level of TGF- production from PPc, the same
evel was always produced regardless of the quantity of antigen
sed for stimulation and regardless of the administration of OVA.
hile the reason for this observation remains uncertain, stimula-ls were collected and stained with immunoﬂuorescence-labeled CD4  and Foxp3
 FITC-labeled anti-Foxp3, and these cells were then measured using FACScan. Data
.). *1 P < 0.001; *2 P < 0.002; *3 P < 0.003; *4 P < 0.006.
tion with enteric bacteria or food might always produce the same
results.
The PPc from the GATA-3/TCR-Tg mice used in the present study
exhibited mainly IL-5 production after the oral immunization of the
mice with OVA plus CTB. Furthermore, the results suggested that
with the addition of CTB to OVA, the amount of IgA produced was
enhanced by the increased production of TGF- associated with the
recovery of the percentage of CD4+Foxp3+ cells.
Because other groups have also described the importance of IL-5
and TGF- in IgA antibody production, our models appeared to be
suitable for eliciting the efﬁcient production of IgA (Sonoda et al.,
1989). The onset trend for the deposition of isotypic antibody in the
glomeruli, the cytokine-producing proﬁles, and the percentages of
Treg cells indicated that the clinical condition arises as a result of
alterations in the Th1/Th2 balance. So far, other groups have sug-
gested the contribution of Th1/Th2 balance to the pathogenesis of
IgAN (Chintalacharuvu et al., 1997, 2001, 2008; Kobayashi et al.,
2002).
Recently, Kuwahara et al. (2012) reported that TGF- inhib-
ited Th2-type immune responses. However, we were not able to
show that the enhanced production of TGF- following immuniza-
tion with OVA plus CTB suppressed Th2-type cytokine production
in PPc from GATA-3/TCR-Tg mice. Furthermore, TGF- production
was suppressed in spleen cells from GATA-3/TCR-Tg mice following
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mmunization with OVA plus CTB. However, the production of IL-2
nd IFN-, both Th1-type cytokines, recovered to the same extent
s that from the spleen in the untreated mice, despite the absence
f the suppression of Th2-type cytokine production. We  previously
eported that a contradiction might exist between the peripheral
mmune responses in the spleen and mucosal immune responses in
he mesenteric lymph nodes, especially in this experimental system
nvolving the use of OVA (Tamauchi et al., 2005).
The existence of both T cell-dependent (TD) and T cell-
ndependent (TI) pathways has been reported for the production
f IgA. Plasmacytoid dendritic cells (pDCs) in Peyer’s patches are
nvolved in IgA production, and pDCs in mesenteric lymph nodes
MLN) are involved in TI IgA production. The expressions of a
roliferation-inducing ligand (APRIL) and B cell-activating factor
f the tumor necrosis factor family (BAFF) in pDCs are important,
nd these factors are reported to control IgA antibody production
Tezuka et al., 2011).
Also, there is a report suggesting that in BAFF-overexpressing Tg
ice, IgA antibody production against commensal bacteria and the
eposition of IgA in the glomeruli are enhanced, and these ﬁndings
uggest that mucosal immunity is involved in the deposition of IgA
n the glomeruli in IgAN (McCarthy et al., 2011).
In the present study, we did not analyze pDCs. However, the
ontribution of pDCs was suggested, since OVA, which was used
s the antigen, is a TD antigen. It is unknown whether APRIL and
AFF in pDCs play important roles in the deposition of IgA in the
lomeruli even though they are closely involved in the production
f IgA. Also, the possible involvement of TI in our experimental
ystem cannot be excluded.
These ﬁndings suggest that the deposition of IgA in the glomeruli
n IgAN is induced by a Th2-type cytokine (IL-5) involved in mucosal
mmunity and a Th1-type cytokine (IL-2 and IFN- production)
nvolved in systemic immunity, and the possible involvement
f TGF- production in the development of IgAN has also been
uggested (Border et al., 1990; Chihara et al., 2006). Regarding T-
ependent IgA antibody production, mutual interactions between
D40 and CD40L, which are co-stimulatory molecules, are report-
dly important (Stavnezer, 1996).
As for the deposition of IgA antibody in the glomeruli, it was  sug-
ested that the recovery of the Th1-type immune response through
he failure of systemic acquired tolerance and the enhanced
L-5 production associated with the Th2-type mucosal immune
esponse may  be involved.
In this model, hematuria and albuminuria were not detected in
he GATA-3/TCR-Tg mouse model. Therefore, which factors may  be
ecessary to induce hematuria and albuminuria should be exam-
ned in detail.
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